The Relationship of Visfatin Levels with Insulin Resistance and Left Ventricular Hypertrophy in Peritoneal Dialysis Patients
Background/objectives: Cardiovascular abnormalities are common in patients with chronic kidney disease. Visfatin influences lipid metabolism, insulin sensitivity, and cardiovascular health. The aim of this study was to explore the relation of serum visfatin to cardiovascular risk factors in nondiabe...
Gespeichert in:
| Veröffentlicht in: | Renal failure 2012-07, Vol.34 (6), p.732-737 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 737 |
|---|---|
| container_issue | 6 |
| container_start_page | 732 |
| container_title | Renal failure |
| container_volume | 34 |
| creator | Karakan, Sebnem Sezer, Siren Özdemir Acar, F. Nurhan Haberal, Mehmet |
| description | Background/objectives: Cardiovascular abnormalities are common in patients with chronic kidney disease. Visfatin influences lipid metabolism, insulin sensitivity, and cardiovascular health. The aim of this study was to explore the relation of serum visfatin to cardiovascular risk factors in nondiabetic peritoneal dialysis (PD) patients. Patients and methods: Eighty-seven nondiabetic patients (mean age 48 ± 15 years, 39 males) under PD were enrolled. Weight, anthropometric measurements, blood pressure, biochemical parameters, and insulin resistance (homeostatic model assessment-insulin resistance-HOMA-IR) were measured. Visfatin was measured and left ventricular mass index (LVMI) was calculated by echocardiography. Results: LVMI was correlated with body mass index (BMI; r = 0.47, p = 0.01), systolic blood pressure (SBP; r = 0.62, p = 0.04), and serum visfatin levels (r = 0.49, p = 0.03). According to HOMA-IR levels patients were grouped as insulin-resistant (IR) (HOMA-IR ≥2.0, n = 35) and noninsulin-resistant (non-IR) (HOMA-IR |
| doi_str_mv | 10.3109/0886022X.2012.676493 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_3109_0886022X_2012_676493</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1020046974</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-69b8b3a6763ed69d2eb3e139155eab42c04061921bcdb69654e4bc4d5825685c3</originalsourceid><addsrcrecordid>eNp9kE1rFTEUhoMo9lr9ByJZuplrkklyJxtF6kcLFyylFndDJnOGSclNxiTTMuCPN8NtBTddBQ7P-56cB6G3lGxrStQH0jSSMPZrywhlW7mTXNXP0IYKJipJuHqONitSrcwJepXSLSFUNDv2Ep0wJkhNlNigP9cj4CtwOtvg02gnHAZ8Y9NQBh7v4Q5cwvc2j_jCp9mV2RUkm7L2BrD2fUGGjG_A52jN7HTE58sEMccwjQsu-CVEm4MH7fAXq91SwviylJdEeo1eDNolePPwnqKf375en51X-x_fL84-7yvDaZMrqbqmq3U5sYZeqp5BVwOtFRUCdMeZIZxIqhjtTN9JJQUH3hnei4YJ2QhTn6L3x94pht8zpNwebDLgnPYQ5tRSwgjhUu14QfkRNTGkFGFop2gPOi4Falfv7aP3dvXeHr2X2LuHDXN3gP5f6FF0AT4dAeuHEA_6PkTXt1kvLsQhFps2rfVPrvj4X8NYlObR6AjtbZijLwKf_uNfuo-naA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1020046974</pqid></control><display><type>article</type><title>The Relationship of Visfatin Levels with Insulin Resistance and Left Ventricular Hypertrophy in Peritoneal Dialysis Patients</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Karakan, Sebnem ; Sezer, Siren ; Özdemir Acar, F. Nurhan ; Haberal, Mehmet</creator><creatorcontrib>Karakan, Sebnem ; Sezer, Siren ; Özdemir Acar, F. Nurhan ; Haberal, Mehmet</creatorcontrib><description>Background/objectives: Cardiovascular abnormalities are common in patients with chronic kidney disease. Visfatin influences lipid metabolism, insulin sensitivity, and cardiovascular health. The aim of this study was to explore the relation of serum visfatin to cardiovascular risk factors in nondiabetic peritoneal dialysis (PD) patients. Patients and methods: Eighty-seven nondiabetic patients (mean age 48 ± 15 years, 39 males) under PD were enrolled. Weight, anthropometric measurements, blood pressure, biochemical parameters, and insulin resistance (homeostatic model assessment-insulin resistance-HOMA-IR) were measured. Visfatin was measured and left ventricular mass index (LVMI) was calculated by echocardiography. Results: LVMI was correlated with body mass index (BMI; r = 0.47, p = 0.01), systolic blood pressure (SBP; r = 0.62, p = 0.04), and serum visfatin levels (r = 0.49, p = 0.03). According to HOMA-IR levels patients were grouped as insulin-resistant (IR) (HOMA-IR ≥2.0, n = 35) and noninsulin-resistant (non-IR) (HOMA-IR <2.0, n = 52) groups. The IR group had longer PD duration and higher BMI, total cholesterol, uric acid, and serum visfatin levels (p < 0.05). The study patients were divided into three groups according to their serum visfatin levels. Group 1 (≤34 ng/mL, n = 22) was considered as the lowest tertile of low visfatin and group 2 (35-42 ng/mL, n = 43) and group 3 (≥43 ng/mL, n = 22) in the upper tertile. Considering the visfatin groups, group 3 patients had significantly higher BMI (p = 0.00), total cholesterol (p = 0.03), C-reactive protein (CRP) (p = 0.03), HOMA-IR (p = 0.03), and LVMI (p = 0.02). In regression analysis, SBP (β = 0.19, p < 0.05) and serum visfatin levels (β = 0.74, p < 0.05) were independent variables affecting LVMI. Conclusion: Serum visfatin might be a sensitive marker than HOMA-IR evaluations for cardiac performance in nondiabetic PD patients.</description><identifier>ISSN: 0886-022X</identifier><identifier>EISSN: 1525-6049</identifier><identifier>DOI: 10.3109/0886022X.2012.676493</identifier><identifier>PMID: 22503095</identifier><language>eng</language><publisher>England: Informa Healthcare</publisher><subject>Adult ; Aged ; Anthropometry ; Biomarkers - blood ; Cross-Sectional Studies ; Echocardiography ; Female ; Humans ; Hypertrophy, Left Ventricular - blood ; Hypertrophy, Left Ventricular - diagnostic imaging ; Hypertrophy, Left Ventricular - etiology ; Insulin Resistance ; Kidney Failure, Chronic - blood ; Kidney Failure, Chronic - complications ; Kidney Failure, Chronic - therapy ; Male ; Middle Aged ; Nicotinamide Phosphoribosyltransferase - blood ; Peritoneal Dialysis ; Regression Analysis ; Risk Factors ; Statistics, Nonparametric ; visfatin</subject><ispartof>Renal failure, 2012-07, Vol.34 (6), p.732-737</ispartof><rights>2012 Informa Healthcare USA, Inc. 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-69b8b3a6763ed69d2eb3e139155eab42c04061921bcdb69654e4bc4d5825685c3</citedby><cites>FETCH-LOGICAL-c418t-69b8b3a6763ed69d2eb3e139155eab42c04061921bcdb69654e4bc4d5825685c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22503095$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karakan, Sebnem</creatorcontrib><creatorcontrib>Sezer, Siren</creatorcontrib><creatorcontrib>Özdemir Acar, F. Nurhan</creatorcontrib><creatorcontrib>Haberal, Mehmet</creatorcontrib><title>The Relationship of Visfatin Levels with Insulin Resistance and Left Ventricular Hypertrophy in Peritoneal Dialysis Patients</title><title>Renal failure</title><addtitle>Ren Fail</addtitle><description>Background/objectives: Cardiovascular abnormalities are common in patients with chronic kidney disease. Visfatin influences lipid metabolism, insulin sensitivity, and cardiovascular health. The aim of this study was to explore the relation of serum visfatin to cardiovascular risk factors in nondiabetic peritoneal dialysis (PD) patients. Patients and methods: Eighty-seven nondiabetic patients (mean age 48 ± 15 years, 39 males) under PD were enrolled. Weight, anthropometric measurements, blood pressure, biochemical parameters, and insulin resistance (homeostatic model assessment-insulin resistance-HOMA-IR) were measured. Visfatin was measured and left ventricular mass index (LVMI) was calculated by echocardiography. Results: LVMI was correlated with body mass index (BMI; r = 0.47, p = 0.01), systolic blood pressure (SBP; r = 0.62, p = 0.04), and serum visfatin levels (r = 0.49, p = 0.03). According to HOMA-IR levels patients were grouped as insulin-resistant (IR) (HOMA-IR ≥2.0, n = 35) and noninsulin-resistant (non-IR) (HOMA-IR <2.0, n = 52) groups. The IR group had longer PD duration and higher BMI, total cholesterol, uric acid, and serum visfatin levels (p < 0.05). The study patients were divided into three groups according to their serum visfatin levels. Group 1 (≤34 ng/mL, n = 22) was considered as the lowest tertile of low visfatin and group 2 (35-42 ng/mL, n = 43) and group 3 (≥43 ng/mL, n = 22) in the upper tertile. Considering the visfatin groups, group 3 patients had significantly higher BMI (p = 0.00), total cholesterol (p = 0.03), C-reactive protein (CRP) (p = 0.03), HOMA-IR (p = 0.03), and LVMI (p = 0.02). In regression analysis, SBP (β = 0.19, p < 0.05) and serum visfatin levels (β = 0.74, p < 0.05) were independent variables affecting LVMI. Conclusion: Serum visfatin might be a sensitive marker than HOMA-IR evaluations for cardiac performance in nondiabetic PD patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Anthropometry</subject><subject>Biomarkers - blood</subject><subject>Cross-Sectional Studies</subject><subject>Echocardiography</subject><subject>Female</subject><subject>Humans</subject><subject>Hypertrophy, Left Ventricular - blood</subject><subject>Hypertrophy, Left Ventricular - diagnostic imaging</subject><subject>Hypertrophy, Left Ventricular - etiology</subject><subject>Insulin Resistance</subject><subject>Kidney Failure, Chronic - blood</subject><subject>Kidney Failure, Chronic - complications</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nicotinamide Phosphoribosyltransferase - blood</subject><subject>Peritoneal Dialysis</subject><subject>Regression Analysis</subject><subject>Risk Factors</subject><subject>Statistics, Nonparametric</subject><subject>visfatin</subject><issn>0886-022X</issn><issn>1525-6049</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1rFTEUhoMo9lr9ByJZuplrkklyJxtF6kcLFyylFndDJnOGSclNxiTTMuCPN8NtBTddBQ7P-56cB6G3lGxrStQH0jSSMPZrywhlW7mTXNXP0IYKJipJuHqONitSrcwJepXSLSFUNDv2Ep0wJkhNlNigP9cj4CtwOtvg02gnHAZ8Y9NQBh7v4Q5cwvc2j_jCp9mV2RUkm7L2BrD2fUGGjG_A52jN7HTE58sEMccwjQsu-CVEm4MH7fAXq91SwviylJdEeo1eDNolePPwnqKf375en51X-x_fL84-7yvDaZMrqbqmq3U5sYZeqp5BVwOtFRUCdMeZIZxIqhjtTN9JJQUH3hnei4YJ2QhTn6L3x94pht8zpNwebDLgnPYQ5tRSwgjhUu14QfkRNTGkFGFop2gPOi4Falfv7aP3dvXeHr2X2LuHDXN3gP5f6FF0AT4dAeuHEA_6PkTXt1kvLsQhFps2rfVPrvj4X8NYlObR6AjtbZijLwKf_uNfuo-naA</recordid><startdate>201207</startdate><enddate>201207</enddate><creator>Karakan, Sebnem</creator><creator>Sezer, Siren</creator><creator>Özdemir Acar, F. Nurhan</creator><creator>Haberal, Mehmet</creator><general>Informa Healthcare</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201207</creationdate><title>The Relationship of Visfatin Levels with Insulin Resistance and Left Ventricular Hypertrophy in Peritoneal Dialysis Patients</title><author>Karakan, Sebnem ; Sezer, Siren ; Özdemir Acar, F. Nurhan ; Haberal, Mehmet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-69b8b3a6763ed69d2eb3e139155eab42c04061921bcdb69654e4bc4d5825685c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anthropometry</topic><topic>Biomarkers - blood</topic><topic>Cross-Sectional Studies</topic><topic>Echocardiography</topic><topic>Female</topic><topic>Humans</topic><topic>Hypertrophy, Left Ventricular - blood</topic><topic>Hypertrophy, Left Ventricular - diagnostic imaging</topic><topic>Hypertrophy, Left Ventricular - etiology</topic><topic>Insulin Resistance</topic><topic>Kidney Failure, Chronic - blood</topic><topic>Kidney Failure, Chronic - complications</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nicotinamide Phosphoribosyltransferase - blood</topic><topic>Peritoneal Dialysis</topic><topic>Regression Analysis</topic><topic>Risk Factors</topic><topic>Statistics, Nonparametric</topic><topic>visfatin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karakan, Sebnem</creatorcontrib><creatorcontrib>Sezer, Siren</creatorcontrib><creatorcontrib>Özdemir Acar, F. Nurhan</creatorcontrib><creatorcontrib>Haberal, Mehmet</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Renal failure</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karakan, Sebnem</au><au>Sezer, Siren</au><au>Özdemir Acar, F. Nurhan</au><au>Haberal, Mehmet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Relationship of Visfatin Levels with Insulin Resistance and Left Ventricular Hypertrophy in Peritoneal Dialysis Patients</atitle><jtitle>Renal failure</jtitle><addtitle>Ren Fail</addtitle><date>2012-07</date><risdate>2012</risdate><volume>34</volume><issue>6</issue><spage>732</spage><epage>737</epage><pages>732-737</pages><issn>0886-022X</issn><eissn>1525-6049</eissn><abstract>Background/objectives: Cardiovascular abnormalities are common in patients with chronic kidney disease. Visfatin influences lipid metabolism, insulin sensitivity, and cardiovascular health. The aim of this study was to explore the relation of serum visfatin to cardiovascular risk factors in nondiabetic peritoneal dialysis (PD) patients. Patients and methods: Eighty-seven nondiabetic patients (mean age 48 ± 15 years, 39 males) under PD were enrolled. Weight, anthropometric measurements, blood pressure, biochemical parameters, and insulin resistance (homeostatic model assessment-insulin resistance-HOMA-IR) were measured. Visfatin was measured and left ventricular mass index (LVMI) was calculated by echocardiography. Results: LVMI was correlated with body mass index (BMI; r = 0.47, p = 0.01), systolic blood pressure (SBP; r = 0.62, p = 0.04), and serum visfatin levels (r = 0.49, p = 0.03). According to HOMA-IR levels patients were grouped as insulin-resistant (IR) (HOMA-IR ≥2.0, n = 35) and noninsulin-resistant (non-IR) (HOMA-IR <2.0, n = 52) groups. The IR group had longer PD duration and higher BMI, total cholesterol, uric acid, and serum visfatin levels (p < 0.05). The study patients were divided into three groups according to their serum visfatin levels. Group 1 (≤34 ng/mL, n = 22) was considered as the lowest tertile of low visfatin and group 2 (35-42 ng/mL, n = 43) and group 3 (≥43 ng/mL, n = 22) in the upper tertile. Considering the visfatin groups, group 3 patients had significantly higher BMI (p = 0.00), total cholesterol (p = 0.03), C-reactive protein (CRP) (p = 0.03), HOMA-IR (p = 0.03), and LVMI (p = 0.02). In regression analysis, SBP (β = 0.19, p < 0.05) and serum visfatin levels (β = 0.74, p < 0.05) were independent variables affecting LVMI. Conclusion: Serum visfatin might be a sensitive marker than HOMA-IR evaluations for cardiac performance in nondiabetic PD patients.</abstract><cop>England</cop><pub>Informa Healthcare</pub><pmid>22503095</pmid><doi>10.3109/0886022X.2012.676493</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0886-022X |
| ispartof | Renal failure, 2012-07, Vol.34 (6), p.732-737 |
| issn | 0886-022X 1525-6049 |
| language | eng |
| recordid | cdi_crossref_primary_10_3109_0886022X_2012_676493 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Aged Anthropometry Biomarkers - blood Cross-Sectional Studies Echocardiography Female Humans Hypertrophy, Left Ventricular - blood Hypertrophy, Left Ventricular - diagnostic imaging Hypertrophy, Left Ventricular - etiology Insulin Resistance Kidney Failure, Chronic - blood Kidney Failure, Chronic - complications Kidney Failure, Chronic - therapy Male Middle Aged Nicotinamide Phosphoribosyltransferase - blood Peritoneal Dialysis Regression Analysis Risk Factors Statistics, Nonparametric visfatin |
| title | The Relationship of Visfatin Levels with Insulin Resistance and Left Ventricular Hypertrophy in Peritoneal Dialysis Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T17%3A13%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Relationship%20of%20Visfatin%20Levels%20with%20Insulin%20Resistance%20and%20Left%20Ventricular%20Hypertrophy%20in%20Peritoneal%20Dialysis%20Patients&rft.jtitle=Renal%20failure&rft.au=Karakan,%20Sebnem&rft.date=2012-07&rft.volume=34&rft.issue=6&rft.spage=732&rft.epage=737&rft.pages=732-737&rft.issn=0886-022X&rft.eissn=1525-6049&rft_id=info:doi/10.3109/0886022X.2012.676493&rft_dat=%3Cproquest_cross%3E1020046974%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1020046974&rft_id=info:pmid/22503095&rfr_iscdi=true |